EP0635507A1 — Tricyclic derivatives and their use as anti-cancer agents
Assigned to AstraZeneca UK Ltd · Expires 1995-01-25 · 31y expired
What this patent protects
The invention concerns tricyclic derivatives of the formula I wherein R¹ and R² together form an optionally substituted group of the formula -N=CH-NH-, -N=CH-O-, -N=CH-S-, -N=N-NH-, -NH-N=CH-, -NH-CH=CH-. -NH-CO-NH-, -NH-CO-O-, -NH-CO-S-, -NH-NH-CO-, -N=CH-CH=N-, -N=N-CH…
USPTO Abstract
The invention concerns tricyclic derivatives of the formula I wherein R¹ and R² together form an optionally substituted group of the formula -N=CH-NH-, -N=CH-O-, -N=CH-S-, -N=N-NH-, -NH-N=CH-, -NH-CH=CH-. -NH-CO-NH-, -NH-CO-O-, -NH-CO-S-, -NH-NH-CO-, -N=CH-CH=N-, -N=N-CH=CH-, -N=CH-N=CH-, -N=CH-CH=N-, -NH-CO-CH=CH- or -N=CH-CO-NH-; m is 1, 2 or 3 and R³ includes hydrogen, halogeno and (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.